Lin Bioscience Stock

Lin Bioscience Equity

The The Equity of Lin Bioscience (6696.TWO) as of Sep 5, 2026 is 10.73 B TWD. In the previous year, The Equity was 2.85 B TWD — a change of 275.93% (higher).

Equity

10.73 BTWD

YoY

275.93%

Last updated:

In 2026, Lin Bioscience's equity was 10.73 B TWD, a 275.93% increase from the 2.85 B TWD equity in the previous year.

The Lin Bioscience Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
377.49 M TWD
Jan 1, 2019
141.81 M TWD
Jan 1, 2020
912.34 M TWD
Jan 1, 2021
541.57 M TWD
Jan 1, 2022
1.23 B TWD
Jan 1, 2023
2.14 B TWD
Jan 1, 2024
2.85 B TWD
Jan 1, 2025
10.73 B TWD
The Lin Bioscience Equity history
YEAREquityYoY
10.73 BTWD+275.93%
2.85 BTWD+33.57%
2.14 BTWD+73.19%
1.23 BTWD+127.89%
541.57 MTWD-40.64%
912.34 MTWD+543.35%
141.81 MTWD-62.43%
377.49 MTWD-27.03%
517.30 MTWD+8.25%
477.86 MTWD—
Access this data via the Eulerpool API
Get Free API Key

Lin Bioscience Stock analysis

What does Lin Bioscience do? Lin Bioscience is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Lin Bioscience's Equity

Lin Bioscience's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Lin Bioscience's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Lin Bioscience's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Lin Bioscience's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Lin Bioscience’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Lin Bioscience stock

The Equity of Lin Bioscience is 10.73 B TWD in 2026.

The Equity of Lin Bioscience changed from 2.85 B TWD to 10.73 B TWD, representing a 275.93% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Lin Bioscience since 2006 – with annual values, charts, and detailed analysis.

The Equity's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Lin Bioscience historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — Lin Bioscience

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Lin Bioscience